Bessemer Group’s Neumora Therapeutics NMRA Stock Holding History

Bessemer Group’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-120	Closed	-$2K	–	2614
2024 Q3	$2K	Buy	+120	New	+$1.4K	﹤0.01%	2240

Other funds holding NMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Bessemer Group's NMRA Position: Q4 2024 in Review

Bessemer Group sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 120 shares — an estimated $2K sold.

Bessemer Group first reported a position in NMRA in Q3 2024 and held it in 1 quarter. The position peaked at $2K in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

Bessemer Group reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 120 Neumora Therapeutics shares in Q4 2024, an estimated $2K.
Bessemer Group first reported a position in Neumora Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Neumora Therapeutics position peaked at $2K in Q3 2024.
134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.